Navigation Links
New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon

tory organ). The composite score of each individual sensory test characterizes the overall level of a person's performance.

Results found that compared to placebo, a significant decrease in SOT composite score was observed with zolpidem (P<0.001), but not with ramelteon (P=0.837). Additional results showed:

    * Significant increase in turn time and turn sway versus placebo was seen

      with zolpidem (P<0.001, both), but not with ramelteon (P=0.776, P=0.982,


      respectively).


    * Immediate memory recall declined significantly with zolpidem (P=0.002),

      but not with ramelteon (P=0.683).


    * Adverse events were reported in 13 patients with zolpidem and seven

      patients each during placebo and ramelteon treatment; none were noted as


      serious.


"This study contributes to the growing body of data showing that ramelteon is a safe option for older adults suffering from insomnia characterized by difficulty with sleep onset," said Zammit. "The trial will also help physicians better understand the unique and differentiating mechanism of action of ramelteon and its potential benefits when making appropriate prescribing decisions for their patients."

About Ramelteon

Ramelteon is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Ramelteon can be prescribed for long-term use. Ramelteon is the first and only prescription sleep medication that has shown no evidence of abuse or dependence in clinical studies,* and has not been designated as a controlled substance. With the exception of ramelteon, all other prescription medications indicated for insomnia are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration.

Ramelteon has a unique therapeutic mechanism of action that selectively targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's "master clock" because it regulates the sl
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/4/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/bqfsp3/transdermal_drug ... PharmaBiotech,s new report "Transdermal Drug Delivery ... their offering. This report ... approach used to deliver drugs through the ... to oral,intravascular, subcutaneous and transmucosal routes. Various ...
(Date:8/4/2015)... 4, 2015 BioElectronics Corporation (OTC Pink: ... Pain Therapy medical devices, announced today that its ... 7-day trial device has been published in the ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic ... an assessment.  Chronic pain is ...
(Date:8/4/2015)... , Aug. 4, 2015  ContraVir Pharmaceuticals, ... focused on the development and commercialization of targeted ... Chief Executive Officer, will present live at VirtualInvestorConferences.com ... August 6, 2015 TIME: 12:15PM EDT LINK: ... a live, interactive online event where investors are ...
Breaking Medicine Technology:Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3
... 5 Transgenomic, Inc. (OTC,Bulletin Board: TBIO), a ... has entered into agreements with two major Pharmaceutical,companies ... $500,000 in the,first half of 2008., "These ... commitments reflect increasing customer validation of our unique,mutation ...
... Inc.,(Amex: PLC ), a company focused on innovative ... for the three,and twelve month periods ended December 31, ... compared with,$1,747,000 in the fourth quarter of 2006. The ... or $0.03 per diluted share, compared to net,income of ...
Cached Medicine Technology:Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies 2PLC Systems Reports Fourth Quarter 2007 Results 2PLC Systems Reports Fourth Quarter 2007 Results 3PLC Systems Reports Fourth Quarter 2007 Results 4PLC Systems Reports Fourth Quarter 2007 Results 5PLC Systems Reports Fourth Quarter 2007 Results 6
(Date:8/4/2015)... St. Louis, Missouri (PRWEB) , ... August 04, ... ... Automated Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership ... 30-year track record of sales success at technology companies and expanding global markets ...
(Date:8/4/2015)... ... , ... Montclair State University and Atlantic Health System have launched a new ... Jersey, which starting this Fall will help prepare those entering this burgeoning, hybrid field. ... System, one of the largest health care organizations in New Jersey, to design the ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s been called “cosmetics ... the customer experience inside Naimie’s Beauty Center in LA. Now MENAJI is part of ... look better. , Naimie’s Beauty Center has been a favorite of makeup artists and ...
(Date:8/4/2015)... (PRWEB) , ... August 04, ... ... its HealthCenter personal health record (PHR) product has achieved Office of the ... Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality personal ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... healthcare finance, announced the closing of a $118 million FHA-insured loan modification refinancing ... located in Smithfield and Clayton, North Carolina. JHSC is a joint venture ...
Breaking Medicine News(10 mins):Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3
... Additional beneficial effects on cardiometabolic risk factors beyond those ... drug rimonabant may not be due to the drug ... Drug and Therapeutics Bulletin (DTB). ,Advertisements ... Sanofi-Aventis) claim that an estimated 50% of the effects ...
... Cryo-Save Group NV together with the University of Cologne ... collect adult mesenchymal stem cells ("MSCs") from the ... allows the collection and cryopreservation of very high quantities ... ,Mesenchymal stem cells (MSCs) are of great therapeutic ...
... current rehab spell will bring a stop to her suicidal ... ,As the Mean Girls star checked into the Promises ... arrested for DUI, her supposed friends got ready to reveal ... America's Star magazine that Lohan attempted to take her own ...
... to enter rehab in order to get rid of his addiction ... was recently snapped in a sleazy romp with two hookers, admitted ... ,"Im a bad boy. I go out and get drunk, ... with the wrong women. Ive been sowing my oats for years, ...
... unabated across the Atlantic. But the man who set off ... Denver that specializes in the disease. The man himself ... Atlanta. He is not coughing, has no fever and does ... said. ,Still, staff at the National Jewish Medical ...
... double current funding levels for the President's Emergency Plan ... years after the program's original mandate expires next year, ... $15 billion over five years for HIV/AIDS and tuberculosis ... the Global Fund To Fight AIDS, Tuberculosis and Malaria. ...
Cached Medicine News:Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2Health News:Significant Scientific Breakthrough in Stem Cell Banking 2Health News:American Who Set Off TB Scare Doing Well in Hospital 2Health News:American Who Set Off TB Scare Doing Well in Hospital 3Health News:Bush Announces Request for $30B, Five-Year Extension of PEPFAR 2
... the latest technology and innovative software with ... transmission and auto detection of progressive lenses. ... network with the VELO 8500 Motorized Refractor ... the future. , ,*VELOtm Aculens 186UV can ...
...
...
...
Medicine Products: